UPM Institutional Repository

Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients


Citation

Karas, Linden A. and Nor Hanipah, Zubaidah and Cetin, Derrick and Schauer, Philip R. and Brethauer, Stacy A. and Daigle, Christopher R. and Aminian, Ali (2020) Assessment of empiric body mass index-based thromboprophylactic dosing of enoxaparin after bariatric surgery: evidence for dosage adjustment using anti-factor Xa in high-risk patients. Surgery for Obesity and Related Diseases, 17 (1). 153 - 160. ISSN 1550-7289; ESSN: 1878-7533

Abstract

Background: Despite thromboprophylaxis, postoperative deep vein thrombosis and pulmonary embolism occur after bariatric surgery, perhaps because of failure to achieve optimal prophylactic levels in the obese population. Objectives: The aim of this study was to evaluate the adequacy of prophylactic dosing of enoxaparin in patients with severe obesity by performing an antifactor Xa (AFXa) assay. Setting: An academic medical center. Methods: In this observational study, all bariatric surgery cases at an academic center between December 2016 and April 2017 who empirically received prophylactic enoxaparin (adjusted by body mass index [BMI] threshold of 50 kg/m2) were studied. The AFXa was measured 3–5 hours after the second dose of enoxaparin. Results: A total of 105 patients were included; 85% were female with a median age of 47 years. In total, 16 patients (15.2%) had AFXa levels outside the prophylactic range: 4 (3.8%) cases were in the subprophylactic and 12 (11.4%) cases were in the supraprophylactic range. Seventy patients had a BMI <50 kg/m2 and empirically received enoxaparin 40 mg every 12 hours; AFXa was subprophylactic in 4 (5.7%) and supraprophylactic in 6 (8.6%) of these patients. Of the 35 patients with a BMI ≥50 who empirically received enoxaparin 60 mg q12h, no AFXa was subprophylactic and 6 (17.1%) were supraprophylactic. Five patients (4.8%) had major bleeding complications. One patient developed pulmonary embolism on postoperative day 35. Conclusion: BMI-based thromboprophylactic dosing of enoxaparin after bariatric surgery could be suboptimal in 15% of patients with obesity. Overdosing of prophylactic enoxaparin can occur more commonly than underdosing. AFXa testing can be a practical way to measure adequacy of pharmacologic thromboprophylaxis, especially in patients who are at higher risk for venous thromboembolism or bleeding.


Download File

[img] Text (Abstract)
ABSTRACT.pdf

Download (110kB)

Additional Metadata

Item Type: Article
Divisions: Faculty of Medicine and Health Science
DOI Number: https://doi.org/10.1016/j.soard.2020.08.016
Publisher: Elsevier
Keywords: Bariatric surgery; Body mass index; Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Prophylaxis; Antifactor Xa; Enoxaparin; Heparin; Low molecular weight heparin
Depositing User: Ms. Nuraida Ibrahim
Date Deposited: 24 May 2022 08:07
Last Modified: 24 May 2022 08:07
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1016/j.soard.2020.08.016
URI: http://psasir.upm.edu.my/id/eprint/87951
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item